Zealand Pharma's peptide-based therapy dasiglucagon Phase 3 clinical trial reaches primary and secondary end points of trial
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, The http://of The Peptide-based Therapy developed by
The Company has reached the primary end and all critical secondary endpoints in the validation of the Phase 3 ClinicalTrial(http://for the treatment of severe hypoglycemia symptoms in diabetic patientsDasiglucagon is a potential "first-in-class" soluble glucagon analogueDasiglucagon is a glucagon analogue developed by Zealand, which has a unique stability and can be stable in the state of aqueous solutionZealand has also developed an auto-injector called HypoPal, which can be operated by diabetics themselves to quickly treat severe hypoglycemiaIn this Phase 3 clinical trial, 45 people with type 1 diabetes participated in the trialThe results showed that after insulin-induced hypoglycemia, a single injection of dasiglucagon with HypoPal was able to begin to restore blood sugar levels within 10 minutes, significantly better than placebo (35 minutes, p0.001), Zealand is currently conducting a Phase 3 clinical trial to test the efficacy of dasiglucagon in pediatric diabeticsThe company is expected to get the results of the clinical trial in September and submit aapplication for new drug(http://to the u.SFDA(http://early next year
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
